This review summarizes bioanalytical methods, pharmacokinetics/pharmacodynamics, and drug-drug interactions of clopidogrel.
Answers are grounded in this paper and cite their sources.
Consolidates clopidogrel bioanalysis, PK/PD, and DDI data; leaves open standardization and prospective validation for clinical use.
Clopidogrel, owing to its excellent inhibitory property of platelet aggregation, is used to reduce the cardiovascular risks in patients with multiple co-morbid conditions such as stroke, myocardial infarction and atherosclerosis. The current review focuses distinctly on three aspects: (a) an in-depth coverage on the bioanalytical methods for the quantification of clopidogrel and its inactive carboxylic acid metabolite as well as the active metabolite in pre-clinical and clinical samples; (b) an overview of the pharmacokinetic/pharmacodynamic aspects of clopidogrel; and (c) enumerating the key findings from drug-drug interaction studies of clopidogrel with various co-substrates such as lanzoprazole, fluvastatin, atorvastatin, pravastatin, digoxin, ketoconazole, donezepil and theophylline.
No takes yet. Share an insight, caveat, or question.
Mullangi et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: